ISSN: 2373-6372GHOA

Gastroenterology & Hepatology: Open Access
Case Report
Volume 4 Issue 5 - 2016
Rectal Carcinoid Tumor in Adolescent Boy
Akash Pandey, Stuart H Berezin*, Natasha Bamji and Larisa Debelenko
Department of Pediatric gastroenterology, hepatology and nutrition, New York Medical College, USA
Received: November 17, 2015 | Published: April 25, 2016
*Corresponding author: Stuart H Berezin, Department of Pediatric gastroenterology, hepatology and nutrition, Maria Fareri Children’s Hospital, Westchester Medical Center, New York Medical College, Suit 201. 503 Grasslands road, Valhalla, New York, USA, Email:
Citation: Pandey A, Berezin SH, Bamji N, Debelenko L (2016) Rectal Carcinoid Tumor in Adolescent Boy. Gastroenterol Hepatol Open Access 4(5): 00113. DOI: 10.15406/ghoa.2016.04.00113

Case Report

The patient is a 17 year old male, who was diagnosed with ulcerative colitis 10 years ago. His treatment was balsalazide. A surveillance colonoscopy was normal except for a small 0.2x 0.2 cms nodular lesion noticed at 15 cms from the anal verge (Figure 1A & B). The nodular lesion was removed by cold biopsy forceps. Biopsies of the terminal ileum were normal. Colonic histology showed chronic minimally active colitis. Histology of the nodular lesion confirmed the diagnosis of rectal carcinoid tumor. Magnetic resonance (MR) enterography and ultrasonography of liver and pancreas were normal. The patient subsequently had an endoscopic ultrasonography with Doppler which did not show any submucosal lesion or rectal wall thickening. There was no indication of residual carcinoid tumor.

Figure 1A: Gross appearance of rectal carcinoid tumor: Colonoscopic appearance of carcinoid showing nodular lesion in rectum.
Figure 1B: Histology of rectal mucosa showing scattered multiple nests of uniform round cells arranged in lace-like pseudorosetting pattern in lamina propria.H&E; original magnification X100.

Neuroendocrine tumors are rare. The incidence is 2.8 cases per million under the age of 30 years. Carcinoid is the most common neuroendocrine tumor of the GI tract [1]. Tumor size larger than 10 mm, presence of central depression, increasing depth of tumor invasion, lymphatic and venous invasion were significantly associated with a higher incidence of lymph node metastasis [2]. Five year survival rate has been reported to range from 54% to 73% for lymph node positive rectal carcinoid disease even without distant metastases [3]. Most patients are asymptomatic but rectal carcinoids can present with rectal bleeding, abdominal pain, diarrhea and flushing of the skin. Rectal carcinoids are essentially chemo resistant [4]. Surgical resection of metastatic lesions improves survival [5]. Preoperative assessment with EUS for rectal carcinoids is effective to determine depth of invasion [6].


  1. Navalkele P, O Dorisio M, O Dorisio TM (2010) Neuroendocrine tumors in children and young adults incidence, survival, and prevalence in the United States. Pancreas 29: 278.
  2. Kasuga A, Chino A, Uragami N, Kishihara T, Igarashi M, et al. (2012) Treatment strategy for rectal carcinoids: a clinicopathological analysis of 229 cases at a single cancer institution. J Gastroenterol Hepatol 27(12):1801-1807.
  3. Konishi T, Watanabe T, Kishimoto J, Kotake K, Muto T, et al. (2007) Prognosis and risk factors of metastasis in colorectal carcinoids: results of a nationwide registry over 15 years. Gut 56(6): 863-868.
  4. Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, et al. (2003) Update on the treatment of neuroendocrine tumors. Expert Rev. Anticancer Ther 3(5): 631-642.
  5. Niederhuber JE, Fojo T (2006) Treatment of metastatic disease in patients with neuroendocrine tumors. Surg Oncol Clin N Am 15(3): 511-533.
  6. Ishii N, Horiki N, Itoh T, Maruyama M, Matsuda M, et al. (2009) Endoscopic submucosal dissection and preoperative assessment with endoscopic ultrasonography for the treatment of rectal carcinoid tumors. Surg Endosc 24(6): 1413-1419.
© 2014-2018 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy